Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand
11:13am, Tuesday, 29'th Jul 2025
Incyte Corporation INCY reported on Tuesday that its second-quarter revenue was $1.22 billion, up 16% year over year. The company beat the consensus of $1.15 billion.
Incyte (INCY) Reports Q2 Earnings: What Key Metrics Have to Say
10:31am, Tuesday, 29'th Jul 2025
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to
Incyte (INCY) Surpasses Q2 Earnings and Revenue Estimates
09:21am, Tuesday, 29'th Jul 2025
Incyte (INCY) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.39 per share. This compares to a loss of $1.82 per share a year ago.
Incyte lifts annual sales forecast for blood cancer drug after solid quarter
08:30am, Tuesday, 29'th Jul 2025
Incyte Corp on Tuesday raised its annual sales forecast for blood cancer treatment Jakafi after robust demand helped the company surpass Wall Street estimates for second-quarter revenue and profit.
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
07:00am, Tuesday, 29'th Jul 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:50am, Monday, 28'th Jul 2025
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Data for Incyte's TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and Selective Inhibitor of G12D-mutated KRAS (INCB161734) Accepted at ESMO 2025.
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
12:46pm, Thursday, 24'th Jul 2025
INCY eyes strong Q2 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
11:06am, Tuesday, 22'nd Jul 2025
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
INCY or TECH: Which Is the Better Value Stock Right Now?
12:41pm, Wednesday, 16'th Jul 2025
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Incyte (INCY) or Techne (TECH). But which of these two stocks is more attractive to value inv
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:50am, Thursday, 10'th Jul 2025
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Incyte to Report Second Quarter Financial Results
08:00am, Thursday, 10'th Jul 2025
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 29, 202
Incyte: New CEO Brings A New Possible Outcome
06:11am, Thursday, 03'rd Jul 2025
Incyte's new CEO, Bill Meury, signals a potential strategic pivot toward M&A, leveraging his biopharma acquisition experience. Jakafi and Opzelura remain the company's primary revenue drivers, with Ja
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 02'nd Jul 2025
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
10:36am, Tuesday, 01'st Jul 2025
INCY stock climbs 9.2% in three months as FDA approvals and a new diagnostic deal fuel pipeline momentum.
